Tsuyoshi Fukuda

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 34:671-9. 2012
  2. pmc Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 33:658-62. 2011
  3. pmc OCT1 genetic variants influence the pharmacokinetics of morphine in children
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, OH, USA
    Pharmacogenomics 14:1141-51. 2013
  4. pmc Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Clin Pharmacol 51:309-20. 2011
  5. pmc Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Br J Clin Pharmacol 73:727-40. 2012
  6. pmc Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus
    Anna Carmela P Sagcal-Gironella
    Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Semin Arthritis Rheum 40:307-13. 2011
  7. pmc Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period
    Min Dong
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Br J Clin Pharmacol 78:1102-12. 2014
  8. doi Effects of unbound mycophenolic Acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients
    Thomas A Smits
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah and Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Ther Drug Monit 36:716-23. 2014
  9. pmc ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children
    Raja Venkatasubramanian
    Department of Anesthesia, Cincinnati Children s Hospital Medical Center 3333 Burnet Avenue, MLC 2001, Cincinnati, OH 45229, USA
    Pharmacogenomics 15:1297-309. 2014
  10. doi Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Transplantation 93:806-12. 2012

Collaborators

Detail Information

Publications14

  1. pmc UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 34:671-9. 2012
    ..Here, the combined contribution of these genetic variants to MPA pharmacokinetic variability was investigated in pediatric renal transplant recipients who were on mycophenolic mofetil maintenance therapy...
  2. pmc Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 33:658-62. 2011
    ..Here, we evaluated the effects of this potential drug-transporter interaction on MPA-PK in a cohort of patients with childhood-onset systemic lupus erythematosus on mycophenolate mofetil therapy...
  3. pmc OCT1 genetic variants influence the pharmacokinetics of morphine in children
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, OH, USA
    Pharmacogenomics 14:1141-51. 2013
    ..To study variations in intravenous morphine pharmacokinetics in children, we examined the influence of genetic polymorphisms in OCT1...
  4. pmc Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Clin Pharmacol 51:309-20. 2011
    ..Because IMPDH inhibition is well correlated to MPA concentration, pretransplant IMPDH activity may serve as an early marker to guide the initial level of MPA exposure required in a pediatric population...
  5. pmc Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Br J Clin Pharmacol 73:727-40. 2012
    ..This study aimed to develop a population pharmacokinetic (PK) enterohepatic recycling model for MPA in patients with childhood-onset systemic lupus erythematosus (cSLE)...
  6. pmc Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus
    Anna Carmela P Sagcal-Gironella
    Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Semin Arthritis Rheum 40:307-13. 2011
    ..The objectives of this study were to (1) characterize the pharmacokinetics (MPA-PK) and pharmacodynamics (MPA-PD) of MPA and (2) explore the relationship between MPA-PK and cSLE disease activity...
  7. pmc Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period
    Min Dong
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Br J Clin Pharmacol 78:1102-12. 2014
    ..The purpose of this study was to develop a population pharmacokinetic and pharmacodynamic (PK-PD) model for mycophenolic acid (MPA) in paediatric renal transplant recipients in the early post-transplant period...
  8. doi Effects of unbound mycophenolic Acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients
    Thomas A Smits
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah and Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Ther Drug Monit 36:716-23. 2014
    ..In this study, a sensitive low volume high-performance liquid chromatography (HPLC) assay was developed to measure fMPA concentrations to explore the relationship between fMPA and IMPDH activity...
  9. pmc ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children
    Raja Venkatasubramanian
    Department of Anesthesia, Cincinnati Children s Hospital Medical Center 3333 Burnet Avenue, MLC 2001, Cincinnati, OH 45229, USA
    Pharmacogenomics 15:1297-309. 2014
    ..Large interindividual variability in morphine pharmacokinetics could contribute to variability in morphine analgesia and adverse events...
  10. doi Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Transplantation 93:806-12. 2012
    ....
  11. doi The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Clin Pharmacokinet 50:1-24. 2011
    ..Already published population pharmacokinetic models will be examined, and the evolution of these models away from empirical approaches to more mechanism-based models will be discussed...
  12. doi Morphine clearance in children: does race or genetics matter?
    Senthilkumar Sadhasivam
    Department of Anesthesia, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Opioid Manag 8:217-26. 2012
    ....
  13. doi Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy
    Sonata Jodele
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 20:518-25. 2014
    ....
  14. ncbi Optimization of mycophenolic acid therapy using clinical pharmacometrics
    Min Dong
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center
    Drug Metab Pharmacokinet 29:4-11. 2014
    ..Lastly, the potential of using a pharmacodynamic based optimal treatment strategy by focusing on MPA's target enzyme inosine monophosphate dehydrogenase (IMPDH) will be discussed. ..